Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Laura Jacobs

Nurse Practitioner Burlington, KY Nurse Practitioner

NPI 1982982344 CMS profile 11214394

6159 1St Financial Dr, St Elizabeth Physicians, Burlington, KY 41005

Open in the dashboard

General payments

$1,350

69 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laura Jacobs of Burlington, KY is reported in the CMS Open Payments database as having received $1,350 across 69 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $212 11
2024 General $243 12
2023 General $425 17
2022 General $189 11
2021 General $280 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Jacobs
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Laura Jacobs were reported at $212. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Laura Jacobs Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $280 $135 $40–$426 $132
2022 $189 $152 $48–$470 $149
2023 $425 $166 $54–$529 $160
2024 $243 $173 $55–$556 $164
2025 $212 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $575 29 payments
  2. Idorsia Pharmaceuticals US Inc $123 1 payment
  3. Novo Nordisk Inc $91 5 payments
  4. Pfizer Inc. $65 4 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $64 4 payments
  6. Amgen Inc. $52 3 payments
  7. GlaxoSmithKline, LLC. $49 3 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $42 3 payments
  9. Abbott Laboratories $38 2 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $38 2 payments
  11. Other $212 13 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,350 69 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $420 20 payments
  2. QUVIVIQ $123 1 payment
  3. UBRELVY $88 5 payments
  4. QULIPTA $56 3 payments
  5. VRAYLAR Neuroscience $53 3 payments
  6. ELIQUIS $50 3 payments
  7. XIFAXAN $42 3 payments
  8. FreeStyle Libre 2 $38 2 payments
  9. Repatha $37 2 payments
  10. JARDIANCE $37 2 payments
  11. Other $652 41 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 75 drugs

Part D claims

3,049

Median for Nurse Practitioner: 389

Drug cost

$223,950

Median for Nurse Practitioner: $21,885

Branded share of claims

16.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 38 $62,216
Eliquis Apixaban Brand 46 $40,453
Mounjaro Tirzepatide Brand 30 $37,762
Januvia Sitagliptin Phosphate Brand 22 $27,612
Trulicity Dulaglutide Brand 11 $17,488
Savella Milnacipran Hcl Brand 12 $5,067
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 16 $2,364
Levothyroxine Sodium Generic 189 $2,186
Atorvastatin Calcium Generic 212 $1,476
Gabapentin Generic 109 $1,430

The 10 drugs with the highest cost, of 75 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$18,075

Of which drugs: $5,296

Medicare patients

103

Average age 73

Services billed

743

74 women, 29 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Depression 31%
Chronic kidney disease 26%
Diabetes 25%
Ischemic heart disease 25%
Osteoporosis 24%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscv2 vac 30mcg trs-suc im 91320 Office 17 20 $2,788
Vaccine for influenza for injection into muscle 90662 Office 27 28 $2,170

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $120
$120 — —
Wegovy
  • Novo Nordisk Inc $33
$33 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $18
$18 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $15
$15 — —
UBRELVY
  • AbbVie, Inc. $12
$12 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

69 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record